BofA Securities, Goldman Sachs & Co. LLC, Evercore ISI, Guggenheim Securities and Cantor acted as joint bookrunners for the offering.

Metsera, Inc., a clinical-stage biotechnology company specializing in obesity treatments through injectable and oral hormone analog peptides, announced the pricing of its initial public offering ...

A registration statement on Form S-1 (File No. 333-284225) relating to the offering has been filed with the Securities and Exchange Commission and became effective on January 30, 2025. The offering is ...

Metsera, a clinical-stage biotechnology firm, debuted on the Nasdaq Global Select Market today. After initially offering its ...

Metsera Inc. is seeking to raise $292 million in an initial public offering, joining a clutch of health-care firms set to ...

A pair of drugmakers priced their initial public offerings on Thursday, delivering the best month for US health care ...

GT Medical Technologies, announced that it has raised $37 million in Series D financing round. The financing round was led ...

Obesity-drug maker Metsera Inc.’s stock jumped 47% on Friday as the biggest gainer among three initial public offerings ...

In addition, Metsera has granted the underwriters a 30-day option to purchase up to an additional 2,291,666 shares of common stock at the initial public offering price less underwriting discounts ...